These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 37715452)

  • 1. Taming resistant hypertension: The promise of novel pharmacologic approaches and renal denervation.
    Azzam O; Nejad SH; Carnagarin R; Nolde JM; Galindo-Kiuchi M; Schlaich MP
    Br J Pharmacol; 2024 Feb; 181(3):319-339. PubMed ID: 37715452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease.
    Lerma E; White WB; Bakris G
    Postgrad Med; 2023 Apr; 135(3):224-233. PubMed ID: 35392754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Potential Treatments for Resistant Hypertension.
    Janakiraman A; Cohen DL
    Curr Cardiol Rep; 2023 Nov; 25(11):1443-1449. PubMed ID: 37755638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic Review Article: New Drug Strategies for Treating Resistant Hypertension-the Importance of a Mechanistic, Personalized Approach.
    Nardoianni G; Pala B; Scoccia A; Volpe M; Barbato E; Tocci G
    High Blood Press Cardiovasc Prev; 2024 Mar; 31(2):99-112. PubMed ID: 38616212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistant hypertension: Renal denervation or intensified medical treatment?
    Morganti A; Mancia G
    Eur J Intern Med; 2018 Apr; 50():6-11. PubMed ID: 29287767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypertension in chronic kidney disease-treatment standard 2023.
    Georgianos PI; Agarwal R
    Nephrol Dial Transplant; 2023 Nov; 38(12):2694-2703. PubMed ID: 37355779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study.
    Rosa J; Widimský P; Toušek P; Petrák O; Čurila K; Waldauf P; Bednář F; Zelinka T; Holaj R; Štrauch B; Šomlóová Z; Táborský M; Václavík J; Kociánová E; Branny M; Nykl I; Jiravský O; Widimský J
    Hypertension; 2015 Feb; 65(2):407-13. PubMed ID: 25421981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baxdrostat: A Novel Aldosterone Synthase Inhibitor for Treatment Resistant Hypertension.
    Dogra S; Shah S; Gitzel L; Pusukur B; Sood A; Vyas AV; Gupta R
    Curr Probl Cardiol; 2023 Nov; 48(11):101918. PubMed ID: 37399857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New approaches in the treatment of hypertension.
    Oparil S; Schmieder RE
    Circ Res; 2015 Mar; 116(6):1074-95. PubMed ID: 25767291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual Endothelin Antagonism with Aprocitentan as a Novel Therapeutic Approach for Resistant Hypertension.
    Heidari Nejad S; Azzam O; Schlaich MP
    Curr Hypertens Rep; 2023 Oct; 25(10):343-352. PubMed ID: 37566184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eplerenone Versus Spironolactone in Resistant Hypertension: an Efficacy and/or Cost or Just a Men's Issue?
    Manolis AA; Manolis TA; Melita H; Manolis AS
    Curr Hypertens Rep; 2019 Mar; 21(3):22. PubMed ID: 30826898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in understanding and managing resistant/refractory hypertension.
    Doumas M; Imprialos KP; Kallistratos MS; Manolis AJ
    F1000Res; 2020; 9():. PubMed ID: 32201574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Device Therapies for Resistant Hypertension.
    Hering D; Schultz C; Schlaich MP
    Clin Ther; 2016 Oct; 38(10):2152-2158. PubMed ID: 27671866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Molecules for Treating Resistant Hypertension: a Clinical Perspective.
    Azzam O; Kiuchi MG; Ho JK; Matthews VB; Gavidia LML; Nolde JM; Carnagarin R; Schlaich MP
    Curr Hypertens Rep; 2019 Sep; 21(10):80. PubMed ID: 31506798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension: 2-year outcomes of randomized PRAGUE-15 study.
    Rosa J; Widimský P; Waldauf P; Zelinka T; Petrák O; Táborský M; Branny M; Toušek P; Čurila K; Lambert L; Bednář F; Holaj R; Štrauch B; Václavík J; Kociánová E; Nykl I; Jiravský O; Rappová G; Indra T; Krátká Z; Widimský J
    J Hypertens; 2017 May; 35(5):1093-1099. PubMed ID: 28118281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug therapy for the patient with resistant hypertension.
    Donazzan L; Ewen S; Papademetriou V; Linicus Y; Linz D; Böhm M; Mahfoud F
    Future Cardiol; 2015 Mar; 11(2):191-202. PubMed ID: 25760878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controversies in Hypertension V: Resistant and Refractory Hypertension.
    Filippone EJ; Naccarelli GV; Foy AJ
    Am J Med; 2024 Jan; 137(1):12-22. PubMed ID: 37832756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on Renal Sympathetic Denervation for the Treatment of Hypertension.
    Rao A; Krishnan N
    Curr Cardiol Rep; 2022 Oct; 24(10):1261-1271. PubMed ID: 35895182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of Sympathetic Overactivity to Treat Resistant Hypertension.
    Voora R; Hinderliter AL
    Curr Hypertens Rep; 2018 Sep; 20(11):92. PubMed ID: 30194545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of resistant hypertension: aldosterone antagonists or intensification of diuretic therapy?
    Verdalles U; García de Vinuesa S; Goicoechea M; Macías N; Santos A; Perez de Jose A; Verde E; Yuste C; Luño J
    Nephrology (Carlton); 2015 Aug; 20(8):567-71. PubMed ID: 25818266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.